Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
<p>Abstract</p> <p>Background</p> <p>Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the mammalian target of rapamycin (mTOR)-inhibitor RAD001...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2011-08-01
|
| Серія: | BMC Cancer |
| Онлайн доступ: | http://www.biomedcentral.com/1471-2407/11/375 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|